Mirikizumab and Alfaspartase AI

TEDAS your procurement assistant

Ask a question about this procurement

t

Procurement Object

  • What is being procured: Purchase of medicines: Mirikizumab and Alfaspartase.
  • Key technical requirements, characteristics:
    • Supply of medicines according to Annex I Technical Specification-Tender Form of the Request for Access to Data (RHAD).
    • Mirikizumab (L04AC24): Concentrate for solution for infusion 300mg/15ml (18 units per year) and solution for injection in a syringe or pen injector 100mg/ml (44 units per year).
    • Alfaspartase (A16AB13): Solution for injection 100mg/ml 0.8ml (650…
       
      To see full summary, please log in or register.
t

👋 Hello! I am TEDAS – your procurement assistant 💼✨

What would you like to know about this procurement?

Note: This is preliminary information. For accuracy, please review all procurement documents.
Ask your questions here...

291463_ESPD_v2.0_laiendatud.xml

291463_hankepass_taiendavate_selgitustega.pdf

291463_hindamiskriteeriumid.pdf

291463_Lisa II Raamlepingu projekt.docx

291463_Lisa I Tehniline kirjeldus-pakkumuse vorm.xlsx

291463_RHAD üldosa.pdf

291463_vastavustingimused.pdf

291463.zip

Ready to get started?

Subscribe and enjoy all the benefits every day!